Finance

Lists
Portfolios
Track your investments in one place, get AI insights, and more
Top movers in your lists
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXT
Technology
SIXT
Technology
SIXT
-2.45%
3,736.96
-93.82
-2.45%
3,830.783,759.433,775.453,712.07
SIXE
Energy
SIXE
Energy
SIXE
+1.68%
1,335.53
+22.10
+1.68%
1,313.431,321.431,336.731,321.43
SIXV
Health care
SIXV
Health care
SIXV
+1.59%
1,713.50
+26.78
+1.59%
1,686.721,692.211,719.801,692.21
SIXI
Industrials
SIXI
Industrials
SIXI
-1.46%
1,849.21
-27.34
-1.46%
1,876.551,867.711,867.711,848.92
SIXR
Staples
SIXR
Staples
SIXR
+1.02%
863.33
+8.69
+1.02%
854.64861.53869.70859.37
US market summary
U.S. stock index futures remained relatively flat following three consecutive days of losses across major benchmarks. The recent downturn was primarily triggered by a sharp selloff in semiconductor and artificial intelligence infrastructure stocks as investors engage in profit-taking and question the sustainability of heavy tech investments.
Dive deeper with AI
Global bond yields ease slightly from multi-decade highs
Treasury yields backed down from their multi-decade highs, bringing brief relief to equity markets ahead of a twenty-year bond auction. The benchmark ten-year note yield dropped slightly to around 4.69%, while longer-dated thirty-year bonds steadied after soaring past 5.33% in previous sessions.
Dive deeper with AI
Retail earnings showcase mixed landscape for consumer discretionary spending
Second-quarter financial reporting highlighted a diverging path for major retail chains. Target managed to outperform expectations and raise its annual sales forecast, whereas Lowe's trimmed its guidance as cautious consumers continue to step back from big-ticket items and home improvement projects.
Dive deeper with AI
Moderna shares rocket upward on successful melanoma vaccine trial
Shares of pharmaceutical developer Moderna surged over 50% in premarket trading following strong clinical data. An interim late-stage trial revealed that its experimental mRNA-based vaccine, administered in combination with Merck's Keytruda, effectively met its primary targets in preventing high-risk skin cancer recurrence.
Dive deeper with AI
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google apps